Abstract
The National Institute for Health and Care Excellence (NICE) offers a fast-track appraisal cost-comparison pathway (FTA) for health technologies that exhibit similar or greater health benefits at a similar or reduced cost to technologies already approved for the same clinical indication. The Scottish Medicines Consortium (SMC) provides two pathways, a full submission using a cost-comparison model or an abbreviated submission requiring a simpler comparison of acquisition costs for interventions and comparators within the same therapeutic class. Recent submissions to NICE and the SMC were reviewed to investigate the use of the SMC pathways and their success rates.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
